Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High – Time to Buy?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) hit a new 52-week high on Friday . The company traded as high as $30.22 and last traded at $29.4570, with a volume of 926134 shares trading hands. The stock had previously closed at $26.99.

Analyst Upgrades and Downgrades

ELVN has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Enliven Therapeutics Stock Up 9.0%

The company has a market capitalization of $1.75 billion, a PE ratio of -15.99 and a beta of 0.34. The firm has a 50-day moving average of $21.31 and a two-hundred day moving average of $20.65.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other news, COO Anish Patel sold 48,300 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the sale, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. This represents a 18.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joseph P. Lyssikatos sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total value of $535,000.00. Following the sale, the insider owned 745,188 shares in the company, valued at $19,933,779. This trade represents a 2.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 252,613 shares of company stock worth $6,519,962. 25.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP grew its holdings in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after purchasing an additional 910,000 shares during the period. TCG Crossover Management LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter valued at approximately $9,990,000. Duquesne Family Office LLC grew its stake in Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after acquiring an additional 484,405 shares during the period. Candriam S.C.A. purchased a new stake in Enliven Therapeutics in the 2nd quarter worth $8,358,000. Finally, Franklin Resources Inc. raised its position in Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after acquiring an additional 410,034 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.